Dexcom

G6, now the previous-generation version of the company’s CGM after the launch of the G7, uses a small, wearable sensor. It also features a transmitter, continuously measuring and sending glucose levels wirelessly to a smart device or receiver. The system enables people with diabetes to receive real-time glucose data without needing to scan or prick their finger.

Dexcom said it showcased the latest clinical evidence at the meeting in Kagoshima, Japan. The company received a non-adjunctive decision and reimbursement expansion in Japan recently based on the clinical data it provided.

Get the full story at our sister site, Drug Delivery Business News.

San Diego-based Dexcom published its study in Diabetes Therapy. It’s titled “Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK.”

The study produced a long-term health economic analysis using the IQVIA CORE Diabetes Model. This allows the calculation of long-term outcomes based on the best data currently available. It establishes the cost-effectiveness for funding Dexcom rtCGM technology against testing with fingerprints.

According to Dexcom, the analysis suggests that rtCGM use results in significant improvements in HbA1c. It also demonstrated reductions in long-term diabetes-related complications and emergency department visits.

Read more

Dexcom (Nasdaq:DXCM) today announced that it intends to offer $1 billion in convertible senior notes due in 2028.

The continuous glucose monitor (CGM) maker made its private placement to persons reasonably considered qualified institutional buyers. San Diego-based Dexcom also plans to grant the initial purchasers of the notes an option to buy more. Those options fall within a 13-day period from, and including, the date of first issuance, for up to an additional $150 million.

Dexcom said in a news release that its notes are senior, unsecured obligations with interest payable semi-annually in arrears. The notes mature on May 15, 2028, unless earlier converted, repurchased or redeemed.

Dexcom earmarked a portion of its net proceeds to pay the cost of capped call transactions. If the initial purchasers exercise their option to buy additional notes, the company intends to use a portion of those proceeds to enter into additional capped call transactions.

Dexcom (Nasdaq:DXCM) today announced that it’s raising its 2023 financial guidance following strong first-quarter financial results.

Shares of DXCM dipped 3.7% to $119 apiece after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 0.2%.

The San Diego-based continuous glucose monitor technology developer posted profits of $48.6 million. That equals 12¢ per share on sales of $741.5 million for the three months ended March 31, 2023.

Dexcom reported a 50% bottom-line slide on sales growth of 17.9%. The company attributed sales growth to strong new customer additions. Dexcom noted this continues to drive revenue growth as awareness of real-time CGM increases.

Get the full story at our sister site, Drug Delivery Business News.

The coverage expansion comes through the Non-Insured Health Benefits (NIHB) program. It now enables any client managing diabetes with insulin to access the standard of care.

Dexcom said its G6 CGM is now at its most accessible point ever under the NIHB program. It marks the highest degree of diabetes management possible for First Nations and Inuit peoples. According to the company, the expansion brings people in Canada one step closer to accessing the technology they need.

This expansion in Canada follows a major Medicare coverage win in the U.S. for Dexcom and CGM makers alike. Earlier this year, the company had another Canadian coverage win, too. Dexcom said in March that all people with type 1 and type 2 diabetes in Manitoba, Canada, meet eligibility criteria for its G6 CGM.

Read more

As of the company’s announcement, Manitoba is the only province in Canada that does not require an application for coverage preapproval. That means improved access for patients and a reduced workload for prescribers.

Expanded coverage establishes Manitoba as the leader in coverage for real-time continuous glucose monitoring (rtCGM) among Canadian provinces.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom (Nasdaq:DXCM) shares ticked up after the market closed today on fourth-quarter results that topped the consensus forecast.

Shares of DXCM rose 2.2% at $109.61 apiece after hours. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 10.1%.

The San Diego-based continuous glucose monitor (CGM) maker posted profits of $91.8 million. That amounts to 22¢ per share on sales of $815.2 million for the three months ended Dec. 31, 2022.

Dexcom recorded a nearly $100 million bottom-line gain out from the red on sales growth of 16.8%.

Get the full story at our sister site, Drug Delivery Business News.